Guidelines & Regulations |
Mithra Mahdavi Aug 26, 2026
Current U.S. recommendations agree that average-risk screening should begin at 40, but they differ on interval and stopping age. Imaging teams should identify the issuing organization whenever they communicate a recommendation.
Mammography screening guidance in the United States has moved closer to consensus in one important respect: screening should begin at age 40 for women at average risk. The remaining disagreement is how often screening should occur and how long it should continue.
The U.S. Preventive Services Task Force issued its current final recommendation in April 2024. It recommends biennial screening mammography for women ages 40 through 74 who are at average risk for breast cancer. The Task Force concluded with moderate certainty that this schedule provides a moderate net benefit.
The USPSTF also identified areas where evidence remains insufficient. These include screening in women age 75 and older and the balance of benefits and harms of supplemental ultrasound or MRI after a negative mammogram, including for women with dense breasts.
That “insufficient evidence” language is important. It does not mean supplemental screening has been shown to be ineffective. It means the USPSTF judged the evidence insufficient to make a population-level recommendation about the balance of benefits and harms.
The American College of Radiology and Society of Breast Imaging continue to recommend annual screening mammography beginning at age 40 for women at average risk. ACR also recommends risk assessment by age 25 so that women at higher-than-average risk can be identified before the standard screening age.
ACR and SBI have also taken a different position on when screening should stop. Rather than using age alone as a hard endpoint, their guidance emphasizes health status and life expectancy.
The central difference, then, is not whether mammography should start at 40. It is the frequency of screening and how the benefits of detecting more cancers earlier are weighed against additional recalls, false-positive examinations and biopsies.
Screening interval changes the window in which a cancer can become clinically apparent between examinations. Annual screening creates more opportunities to identify a cancer before it progresses, but it also produces more screening encounters over a lifetime. More examinations inevitably create more opportunities for recall and benign workup.
Biennial screening reduces the total number of examinations and therefore reduces cumulative screening-related harms, but it also allows a longer interval in which some cancers may develop or progress.
This is why conversations about screening interval should not reduce the issue to a single metric. Mortality reduction, stage at diagnosis, interval cancers, recall, biopsy and patient preference can all influence the interpretation of the evidence.
One of the most important changes in modern breast screening is the move away from treating every patient as if she has the same baseline risk. Family history, pathogenic genetic variants, prior chest radiation, personal history of breast cancer, high-risk breast lesions and breast density can materially change the screening strategy.
ACR recommends that women undergo breast cancer risk assessment by age 25, particularly so that patients who may qualify for earlier mammography or supplemental MRI can be identified before age 40.
For imaging practices, this creates an operational opportunity. Screening intake, scheduling and patient communication can be designed to capture risk information rather than treating risk assessment as a separate downstream conversation.
When patients ask why guidelines conflict, the clearest answer is that major organizations use different methods and place different weight on screening benefits and harms. The organizations are not debating whether mammography saves lives; they are debating the schedule that produces the best balance at the population level.
Practices should avoid presenting one recommendation as if it were the only guideline in existence. Instead, communications can identify the organization, state the recommendation accurately and explain that individual risk may support a different screening plan.
In 2026, the professional conversation is increasingly less about whether to begin average-risk screening at 40 and more about screening interval, individualized risk and the role of supplemental imaging.
For mammography programs, the best operational response is consistency: know which clinical guidance the practice follows, document risk clearly, educate referring providers and make sure patient-facing materials distinguish population recommendations from individualized clinical decisions.
